CSPC PHARMA (01093) released its interim results, with net profit attributable to shareholders reported at 6.094 billion yuan, a year-on-year increase of 139.2%.

CSPC PHARMA (01093) released its mid-year results for 2026, with total revenue amounting to 18.594 billion yuan (RMB, the same hereinafter), a year-on-year increase of 40.1%; profit attributable to shareholders was reported at 6.094 billion yuan, representing a year-on-year growth of 139.2%; basic earnings per share were 53.45 cents. A mid-term dividend of 18.00 Hong Kong cents per share is proposed. The announcement stated that Leading innovation, creating excellence at CSPC is the core vision of CSPC employees. Under the strategic guidance of the chairman, the group has consistently adhered to the dual-drive development strategy of innovation + internationalization, continuously increasing R&D investment and strengthening talent and team building, which has significantly enhanced the groups core competitiveness, injecting strong momentum into the group's long-term sustainable development. The group has an international R&D team of over 2,000 people, with research centers located in major domestic cities and the United States, focusing on core therapeutic areas such as oncology, cardiovascular system, nervous system, respiratory system, anti-infection, and digestive metabolism. We have taken the lead in establishing an industry-leading AI drug discovery technology platform and a globally superior delivery technology system, forming a significant differentiation advantage in the industry. The R&D pipeline covers cutting-edge areas like ADCs, antibody drugs, CAR-T products, long-acting peptide formulations, and nucleic acid drugs. Overall, the group has built eight major innovative R&D platforms including nano-formulations, mRNA, siRNA, antibody/fusion proteins, cell therapies, and antibody-drug conjugates, providing solid technical support for the discovery and transformation of innovative drugs. In the first half of 2026, the group obtained 30 IND approvals, with 7 key products approved for market launch and 18 new key Phase III clinical studies initiated. Since the beginning of the year, several R&D achievements have been published in top medical journals: The Phase I clinical study of SYS6010 for non-small cell lung cancer was accepted by Cancer Cell (impact factor 56.1); the Phase III study results of Docetaxel (albumin-bound) combined with KN026 for neoadjuvant treatment of breast cancer were officially accepted by JAMA Oncology (impact factor 23.9); and the Phase III clinical study results of albumin-bound paclitaxel (SYHX2011) for treating advanced breast cancer patients were accepted by Cancer Communications (impact factor 24.9). These achievements reflect the recognition of the groups research strength by leading international journals. Meanwhile, the group has showcased its core research results at top international academic platforms, including the American Association for Cancer Research (AACR), the American Society of Clinical Oncology (ASCO), and the Society of Gynecologic Oncology (SGO). In just the first half of 2026, the group published 14 research results, including 5 oral presentations, which received positive international feedback and widespread industry attention. Currently, the group has over 200 innovative drugs and formulations under research, including more than 90 macromolecules, over 60 small molecules, and over 50 novel formulations, many of which have broad market prospects and significantly outperform existing therapies in terms of efficacy and safety. CSPC PHARMA's exploration in the field of AI drug development began with the establishment of the CADD (Computer-Aided Drug Design) research lab in 2011. The group has now established an AI drug discovery team spanning Shijiazhuang, Beijing, and Shanghai, forming a technology system centered on the "AI engine dual-drive drug discovery platform." This platform has achieved one-stop development from target discovery, molecular generation, structural prediction to ADMET (absorption, distribution, metabolism, excretion, and toxicity) prediction. The group possesses mature and robust commercialization capabilities, with a professional marketing team of over 10,000 people, broadly covering national medical institutions and retail channels. We are actively promoting market penetration and deeply cultivating the grassroots county market to provide quality medicines to more people. The mature sales system and rich commercialization experience provide a solid guarantee for the market launch and performance of the groups innovative drugs. Looking to the future, the group will continue to drive development through technological innovation and leverage solid commercialization capabilities to realize results, contributing to the high-quality development of China Meheco Group and bringing benefits to more patients.